Kabi Awaits Melrose Park Fate As mAbxience Deal Closes
€455m Deal For 55% Stake In Biosimilars Business Closed 1 August
Fresenius Kabi is pressing on with its ‘Vision 2026’ strategic growth initiatives, with the company wrapping up its acquisition of Insud Pharma’s bio unit mAbxience. However, it remains “to some degree output constrained,” which looks set to continue to impact operations, amid staff shortages.
